Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01395524 · ClinicalTrials.gov registry record · Phase 3
A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 302
- Enrollment target
NCT01395524 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 302 participants.
The verdict
NCT01395524, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 302 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect and safety of NKTR-118 treatment of opioid-induced constipation in patients with non-cancer-related pain over a 6-month period.
Interventions
- DRUG Placebo
- DRUG NKTR-118
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01395524
The ClinicalTrials.gov registry entry for NCT01395524 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01395524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01395524 about?
NCT01395524 is a clinical study titled "A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation". The purpose of this study is to evaluate the effect and safety of NKTR-118 treatment of opioid-induced constipation in patients with non-cancer-related pain over a 6-month period.
What is the current status of trial NCT01395524?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 302 participants. The study started on 2011-07. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01395524?
The interventions under investigation include: Placebo (DRUG), NKTR-118 (DRUG).
Who is sponsoring clinical trial NCT01395524?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.